Show simple item record

Authordc.contributor.authorWinter, José Luis 
Authordc.contributor.authorCastro, Pablo F. es_CL
Authordc.contributor.authorQuintana, Juan Carlos es_CL
Authordc.contributor.authorAltamirano, Rodrigo es_CL
Authordc.contributor.authorEnriquez, Andrés es_CL
Authordc.contributor.authorVerdejo, Hugo E. es_CL
Authordc.contributor.authorJalil Milad, Jorge es_CL
Authordc.contributor.authorMellado, Rose Marie es_CL
Authordc.contributor.authorConcepción, Roberto es_CL
Authordc.contributor.authorSepúlveda, Pablo es_CL
Authordc.contributor.authorRossel Mariangel, Víctor Alejandro es_CL
Authordc.contributor.authorSepúlveda Morales, Luis es_CL
Authordc.contributor.authorChiong Lay, Mario es_CL
Authordc.contributor.authorGarcía Nannig, Lorena es_CL
Authordc.contributor.authorLavandero González, Sergioes_CL
Cita de ítemdc.identifier.citationJournal of Cardiac Failure Vol. 20 No. 3 2014en_US
Identifierdc.identifier.otherDOI: 10.1016/j.cardfail.2014.01.004
General notedc.descriptionArtículo de publicación ISIen_US
Abstractdc.description.abstractObjectives: Heart failure (HF) is associated with changes in myocardial metabolism that lead to impairment of contractile function. Trimetazidine (TMZ) modulates cardiac energetic efficiency and improves outcomes in ischemic heart disease. We evaluated the effects of TMZ on left ventricular ejection fraction (LVEF), cardiac metabolism, exercise capacity, O2 uptake, and quality of life in patients with nonischemic HF. Methods and Results: Sixty patients with stable nonischemic HF under optimal medical therapy were included in this randomized double-blind study. Patients were randomized to TMZ (35 mg orally twice a day) or placebo for 6 months. LVEF, 6-minute walk test (6MWT), maximum O2 uptake in cardiopulmonary exercise test, different markers of metabolism, oxidative stress, and endothelial function, and quality of life were assessed at baseline and after TMZ treatment. Left ventricular peak glucose uptake was evaluated with the use of the maximum standardized uptake value (SUV) by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET). Etiology was idiopathic in 85% and hypertensive in 15%. Both groups were similar in age, functional class, LVEF, and levels of N-terminal proeB-type natriuretic peptide at baseline. After 6 months of TMZ treatment, no changes were observed in LVEF (31 6 10% vs 34 6 8%; P 5 .8), 6MWT (443 6 25 m vs 506 6 79 m; P 5 .03), maximum O2 uptake (19.1 6 5.0 mL kg 1 min 1 vs 23.0 6 7.2 mL kg 1 min 1; P 5 .11), functional class (percentages of patients in functional classes I/II/III/IV 10/3753/0 vs 7/40/50/3; P 5 .14), or quality of life (32 6 26 points vs 24 6 18 points; P 5 .25) in TMZ versus placebo, respectively. In the subgroup of patients evaluated with 18FDG-PET, no significant differences were observed in SUV between both groups (7.0 6 3.6 vs 8.2 6 3.4 respectively; P 5 .47). Conclusions: In patients with nonischemic HF, the addition of TMZ to optimal medical treatment does not result in significant changes of LVEF, exercise capacity, O2 uptake, or quality of life.en_US
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile*
Link to Licensedc.rights.uri*
Títulodc.titleEffects of Trimetazidine in Nonischemic Heart Failure: A Randomized Studyen_US
Document typedc.typeArtículo de revista

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile